The diabetes drug Avandia has taken a lot of heat in recent years because it has been linked to a higher risk of heart attacks. The FDA has just decided that the drug will be severely restricted only to patients who don’t respond well to other diabetes drugs.
Its chief competitor, Actos, has filled the void and captured much of the diabetes drug market share even though it too has a strict warning about causing or exacerbating heart failure. Now, the FDA has added another concern to the Actos prescribing dilemma. Data half way through a ten-year trial suggests that people taking Actos for long periods of time may have a higher risk of bladder cancer. The FDA is not ready to say that Actos actually causes cancer, but it will continue to monitor the data from the long-term study. The agency promises to update the public when it has additional information.

Join Over 52,000 Subscribers at The People's Pharmacy

  1. JAW
    Reply

    My husband went through a serious weight gain with Actos and was taken off the drug….
    He is currently losing the weight now that he is “Actos-Free”.

  2. HW
    Reply

    After taking Actos + Januvia for three mos. I noticed a gradual weight gain towards the end of the time period. I have quit taking Actos & am now working hard to get rid of the ten pounds I had gained. Other than that I did not notice any other reactions.

  3. cpmt
    Reply

    both AVANDIA AND ACTOS have the same risk.

What Do You Think?

Share your thoughts with others, but be mindful of protecting your own and others' privacy. Not all comments will be posted. Advice from web visitors is not a substitute for medical attention. Do not stop any medicine without checking with the prescriber. In posting a comment, you agree to our commenting policy and website terms and conditions.